Search

Your search keyword '"Bazeos, Alexandra"' showing total 33 results
Start Over Author "Bazeos, Alexandra"
33 results on '"Bazeos, Alexandra"'

3. Genome-wide DNA methylation in chronic myeloid leukaemia

Author

Bazeos, Alexandra, Apperley, Jane, and Foroni, Letizia

Subjects
616.99
Abstract

Epigenetic alterations occur frequently in leukaemia and might account for differences in clinical phenotype and response to treatment. Despite the consistent presence of the BCR-ABL1 fusion gene in Philadelphia-positive chronic myeloid leukaemia (CML), the clinical course of patients treated with tyrosine kinase inhibitors (TKI) is heterogeneous. This might be due to differing DNA methylation profiles between patients. Therefore, a validated, epigenome-wide survey in CML CD34+ progenitor cells was performed in newly diagnosed chronic phase patients using array-based DNA methylation and gene expression profiling. In practice, the CML DNA methylation signature was remarkably homogeneous; it differed from CD34+ cells of normal persons and did not correlate with an individual patient's response to TKI therapy. Using a meta-analysis tool it was possible to demonstrate that this signature was highly enriched for developmentally dynamic regions of the human methylome and represents a combination of CML-unique, myeloid leukemia-specific and pan-cancer sub-signatures. The CML profile involved aberrantly methylated genes in signaling pathways already implicated in CML leukaemogenesis, including TGF-beta, Wnt, Jak-STAT and MAPK. Furthermore, a core set of differentially methylated promoters were identified that likely have a role in modulating gene expression levels. In conclusion, the findings are consistent with the notion that CML starts with the acquisition of a BCR-ABL1 fusion gene by a haematopoietic stem cell, which then either causes or cooperates with a series of DNA methylation changes that are specific for CML.

Published
2017
Full Text
View/download PDF

4. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Author

Morschhauser, Franck, Feugier, Pierre, Flinn, Ian W., Gasiorowski, Robin, Greil, Richard, Illés, Árpád, Johnson, Nathalie A., Larouche, Jean-François, Lugtenburg, Pieternella J., Patti, Caterina, Salles, Gilles A., Trněný, Marek, de Vos, Sven, Mir, Farheen, Samineni, Divya, Kim, Su Y., Jiang, Yanwen, Punnoose, Elizabeth, Sinha, Arijit, Clark, Emma, Spielewoy, Nathalie, Humphrey, Kathryn, Bazeos, Alexandra, and Zelenetz, Andrew D.

Published
2021
Full Text
View/download PDF

5. Supplementary Table S3 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Author

Klanova, Magdalena, primary, Oestergaard, Mikkel Z., primary, Trněný, Marek, primary, Hiddemann, Wolfgang, primary, Marcus, Robert, primary, Sehn, Laurie H., primary, Vitolo, Umberto, primary, Bazeos, Alexandra, primary, Goede, Valentin, primary, Zeuner, Harald, primary, Knapp, Andrea, primary, Sahin, Deniz, primary, Spielewoy, Nathalie, primary, Bolen, Christopher R., primary, Cardona, Andres, primary, Klein, Christian, primary, Venstrom, Jeffrey M., primary, Nielsen, Tina, primary, and Fingerle-Rowson, Günter, primary

Published
2023
Full Text
View/download PDF

7. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Author

de Lavallade, Hugues, Khoder, Ahmad, Hart, Melanie, Sarvaria, Anushruti, Sekine, Takuya, Alsuliman, Abdullah, Mielke, Stephan, Bazeos, Alexandra, Stringaris, Kate, Ali, Sara, Milojkovic, Dragana, Foroni, Letizia, Chaidos, Aristeidis, Cooper, Nichola, Gabriel, Ian, Apperley, Jane, Belsey, Sarah, Flanagan, Robert J., Goldman, John, Shpall, Elizabeth J., Kelleher, Peter, Marin, David, and Rezvani, Katayoun

Published
2013
Full Text
View/download PDF

8. Additional file 1 of Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma

Author

Kim, Eugene, Jiang, Yanwen, Xu, Tao, Bazeos, Alexandra, Knapp, Andrea, Bolen, Christopher R., Humphrey, Kathryn, Nielsen, Tina G., Penuel, Elicia, and Paulson, Joseph N.

Abstract

Additional file 1: Supplementary Methods and Results. Supplementary Table S1. Baseline disease characteristics of patients in the BEP and ITT study populations in GOYA and CAVALLI. Supplementary Table S2. Confusion matrix for Random Forest training model. Supplementary Table S3. A. CAVALLI ethics committees (EC) and/or institutional review boards (IRB) of participating centers. B. GOYA ethics committees (EC) and/or institutional review boards (IRB) of participating centers. Supplementary Figure S1. NMF-defined clusters in CAVALLI and their association with cell-of-origin. Supplementary Figure S2. Kaplan-Meier curves of PFS for NMF high- and low-risk prognostic groups in GOYA according to (A) treatment and (B) cell-of-origin (activated B-cell-like vs germinal center B-cell-like). Supplementary Figure S3. Kaplan-Meier curve of PFS for the BCL2/EZH2 versus MYD88/CD798 clusters in CAVALLI (de novo NMF clustering). Supplementary Figure S4. Training of a Random Forest model on NMF cluster labels in GOYA onto CAVALLI. (A) Clustering of gene features of predicted GOYA NMF groups onto CAVALLI. (B) Kaplan-Meier curves of PFS for predicted GOYA NMF groups in CAVALLI. Supplementary Figure S5. Kaplan-Meier curves of PFS for GOYA and CAVALLI. Supplementary Figure S6. Differential expression and pathway analysis of NMF highrisk vs low-risk patients in GOYA. (A) Volcano plot of all genes for patients with NMF risk categorization and RNA-Seq data. Limma was used to determine differential expression with no covariate adjustment. Labelled points outside of the red dotted lines indicate genes with a false discovery rate 1. (B) Pathways with false discovery rate

Published
2022
Full Text
View/download PDF

9. Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

Author

Samineni, Divya, primary, Huang, Weize, additional, Gibiansky, Leonid, additional, Ding, Hao, additional, Zhang, Rong, additional, Li, Chunze, additional, Sinha, Arijit, additional, Rajwanshi, Richa, additional, Humphrey, Kathryn, additional, Bazeos, Alexandra, additional, Salem, Ahmed Hamed, additional, and Miles, Dale, additional

Published
2021
Full Text
View/download PDF

10. Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Author

Falchi, Lorenzo, Jardin, Fabrice, Haioun, Corinne, Wrobel, Tomasz, Joergensen, Judit Mészáros, Bastos-Oreiro, Mariana, Mou, Eric, Martinez-Lopez, Joaquin, Budde, L. Elizabeth, Bartlett, Nancy L., Zaucha, Jan M., Martin Garcia-Sancho, Alejandro, Shah, Rutanshu, Rees, Nathan, McCord, Ron, Bazeos, Alexandra, Tandon, Maneesh, Doral, Michelle, Troy-Barnes, Ethan, and Nijland, Marcel

Published
2023
Full Text
View/download PDF

11. Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Author

Lee, Yeasung, Bladt, Francesca, Leonardos, Dimitrios, Mustafa, Chira, Katsarou, Alexia, Atta, Maria, Bua, Marco, Gabriel, Ian, Ros-Soto, Jose, Bazeos, Alexandra, Pavlu, Jiri, Loaiza, Sandra, Bray, Emma, O'Boyle, Farah, Nadal, Elisabet, Szydlo, Richard, Crump, Nicholas, Karadimitris, Anastasios, and Chaidos, Aristeidis

Published
2023
Full Text
View/download PDF

13. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Author

Klanova, Magdalena, Oestergaard, Mikkel Z., Trneny, Marek, Hiddemann, Wolfgang, Marcus, Robert, Sehn, Laurie H., Vitolo, Umberto, Bazeos, Alexandra, Goede, Valentin, Zeuner, Harald, Knapp, Andrea, Sahin, Deniz, Spielewoy, Nathalie, Bolen, Christopher R., Cardona, Andres, Klein, Christian, Venstrom, Jeffrey M., Nielsen, Tina, Fingerle-Rowson, Guenter, Klanova, Magdalena, Oestergaard, Mikkel Z., Trneny, Marek, Hiddemann, Wolfgang, Marcus, Robert, Sehn, Laurie H., Vitolo, Umberto, Bazeos, Alexandra, Goede, Valentin, Zeuner, Harald, Knapp, Andrea, Sahin, Deniz, Spielewoy, Nathalie, Bolen, Christopher R., Cardona, Andres, Klein, Christian, Venstrom, Jeffrey M., Nielsen, Tina, and Fingerle-Rowson, Guenter

Abstract

Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with worse outcome in patients receiving antibodybased therapy. Patients and Methods: Baseline peripheral blood NKCC was assessed by flow cytometry (CD3(-) CD56(+) and/or CD16(+) cells) in 1,064 of 1,202 patients with follicular lymphoma treated with obinutuzumab or rituximab plus chemotherapy in the phase III GALLIUM trial (NCT01332968) and 1,287 of 1,418 patients with diffuse large B-cell lymphoma (DLBCL) treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP or R-CHOP) in the phase III GOYA trial (NCT01287741). The prognostic value of tumor NK-cell gene expression, as assessed by whole-transcriptome gene expression using TruSeq RNA sequencing, was also analyzed. The association of baseline variables, such as treatment arm, was evaluated using multivariate Cox regression models using a stepwise approach. Results: In this exploratory analysis, low baseline peripheral blood NKCC was associated with shorter progression-free survival (PFS) in both follicular lymphoma [hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.02-2.14; P = 0.04] and DLBCL (HR, 1.36; 95% CI, 1.01-1.83; P = 0.04), and overall survival in follicular lymphoma (HR, 2.20; 95% CI, 1.26-3.86; P = 0.0058). Low tumor NK-cell gene expression was associated with shorter PFS in G-CHOP-treated patients with DLBCL (HR, 1.95; 95% CI, 1.22-3.15; P < 0.01). Conclusions: These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20 based immunochemotherapy.

Published
2019

14. Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

Author

Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Goede, Valentin, Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, and Goede, Valentin

Abstract

In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the German CLL Study Group (GCLLSG) (CLL8, CLL10, CLL11) including a total of 2159 patients receiving first line (immuno)-chemotherapy (FCR, FC, CLB, CLB-R, CLB-Ob) were analyzed. Patients were categorized as ALC if PD was due to increasing absolute lymphocyte count, or as Ly if due to lymphadenopathy. A group of 241 patients progressed with ALC, and 727 progressed with Ly, including 329 who progressed on both modalities. In fit patients, median TTNT after PD in the Ly group was 12.3 months vs 17.0 months in the ALC group (HR 1.299 [1.036-1.628]; P = .024). Median OS after PD was 45.1 months in the Ly group and 42.4 months in the ALC group (HR=1.023 [0.753-1.389]; P = .885). For unfit patients, median TTNT in the Ly group was 11.7 months vs 21.4 months in the ALC group (HR 1.357 [1.051-1.753]; P = .019). Median OS was 42.8 months in the Ly group and not reached in the ALC group (HR 1.851 [1.280-2.677]; P = .001). Patients in the Ly group more frequently showed impairment of quality of life (QoL). This analysis demonstrates that patients with progressive lymphadenopathy have a significantly shorter TTNT, OS and less favorable QoL. Our findings might help physicians to better estimate the clinical course of a progressing CLL patient.

Published
2019

15. Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Author

Kim, Eugene C, primary, Fan, Jinzhen, additional, Bolen, Christopher R, additional, Bazeos, Alexandra, additional, Jiang, Yanwen, additional, Balasubramanian, Sandhya, additional, Balakrishnan, Rama, additional, Knapp, Andrea, additional, Humphrey, Kathryn, additional, Nielsen, Tina G, additional, Venstrom, Jeffrey M., additional, Hernandez, Genevive, additional, and Paulson, Joseph N, additional

Published
2019
Full Text
View/download PDF

16. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Author

Klanova, Magdalena, primary, Oestergaard, Mikkel Z., additional, Trněný, Marek, additional, Hiddemann, Wolfgang, additional, Marcus, Robert, additional, Sehn, Laurie H., additional, Vitolo, Umberto, additional, Bazeos, Alexandra, additional, Goede, Valentin, additional, Zeuner, Harald, additional, Knapp, Andrea, additional, Sahin, Deniz, additional, Spielewoy, Nathalie, additional, Bolen, Christopher R., additional, Cardona, Andres, additional, Klein, Christian, additional, Venstrom, Jeffrey M., additional, Nielsen, Tina, additional, and Fingerle-Rowson, Günter, additional

Published
2019
Full Text
View/download PDF

17. Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

Author

Al‐Sawaf, Othman, primary, Bazeos, Alexandra, additional, Robrecht, Sandra, additional, Bahlo, Jasmin, additional, Gower, Craig, additional, Fink, Anna‐Maria, additional, Tresckow, Julia, additional, Cramer, Paula, additional, Langerbeins, Petra, additional, Kutsch, Nadine, additional, Humphrey, Kathryn, additional, Fingerle‐Rowson, Günter, additional, Stilgenbauer, Stephan, additional, Wendtner, Clemens‐Martin, additional, Fischer, Kirsten, additional, Eichhorst, Barbara, additional, Hallek, Michael, additional, and Goede, Valentin, additional

Published
2019
Full Text
View/download PDF

18. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Author

Nteliopoulos, Georgios, primary, Bazeos, Alexandra, additional, Claudiani, Simone, additional, Gerrard, Gareth, additional, Curry, Edward, additional, Szydlo, Richard, additional, Alikian, Mary, additional, Foong, Hui En, additional, Nikolakopoulou, Zacharoula, additional, Loaiza, Sandra, additional, Khorashad, Jamshid S., additional, Milojkovic, Dragana, additional, Perrotti, Danilo, additional, Gale, Robert Peter, additional, Foroni, Letizia, additional, and Apperley, Jane F., additional

Published
2019
Full Text
View/download PDF

19. Genome-wide DNA methylation in chronic myeloid leukaemia

Author

Bazeos, Alexandra, Apperley, Jane, Foroni, Letizia, and Medical Research Council (Great Britain)

Subjects
hemic and lymphatic diseases
Abstract

Epigenetic alterations occur frequently in leukaemia and might account for differences in clinical phenotype and response to treatment. Despite the consistent presence of the BCR-ABL1 fusion gene in Philadelphia-positive chronic myeloid leukaemia (CML), the clinical course of patients treated with tyrosine kinase inhibitors (TKI) is heterogeneous. This might be due to differing DNA methylation profiles between patients. Therefore, a validated, epigenome-wide survey in CML CD34+ progenitor cells was performed in newly diagnosed chronic phase patients using array-based DNA methylation and gene expression profiling. In practice, the CML DNA methylation signature was remarkably homogeneous; it differed from CD34+ cells of normal persons and did not correlate with an individual patient’s response to TKI therapy. Using a meta-analysis tool it was possible to demonstrate that this signature was highly enriched for developmentally dynamic regions of the human methylome and represents a combination of CML-unique, myeloid leukemia-specific and pan-cancer sub-signatures. The CML profile involved aberrantly methylated genes in signaling pathways already implicated in CML leukaemogenesis, including TGF-beta, Wnt, Jak-STAT and MAPK. Furthermore, a core set of differentially methylated promoters were identified that likely have a role in modulating gene expression levels. In conclusion, the findings are consistent with the notion that CML starts with the acquisition of a BCR-ABL1 fusion gene by a haematopoietic stem cell, which then either causes or cooperates with a series of DNA methylation changes that are specific for CML. Open Access

Published
2016

20. Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Author

Klanova, Magdalena, primary, Oestergaard, Mikkel Z., additional, Trněný, Marek, additional, Hiddemann, Wolfgang, additional, Marcus, Robert, additional, Sehn, Laurie H., additional, Vitolo, Umberto, additional, Bazeos, Alexandra, additional, Goede, Valentin, additional, Zeuner, Harald, additional, Knapp, Andrea, additional, Sahin, Denis, additional, Danesi, Nathalie, additional, Bolen, Christopher, additional, Robson, Susan, additional, Venstrom, Jeffrey M., additional, Nielsen, Tina, additional, and Fingerle-Rowson, Günter, additional

Published
2017
Full Text
View/download PDF

21. Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Author

Bazeos, Alexandra, Gower, Craig, Swann, Francine, Trask, Peter C., Dixon, Mark, Crompton, Noelle, Kinnersley, Nelson, Al-Sawaf, Othman, Goede, Valentin, Fingerle-Rowson, Gunter, Humphrey, Kathryn, Bazeos, Alexandra, Gower, Craig, Swann, Francine, Trask, Peter C., Dixon, Mark, Crompton, Noelle, Kinnersley, Nelson, Al-Sawaf, Othman, Goede, Valentin, Fingerle-Rowson, Gunter, and Humphrey, Kathryn

Published
2016

22. Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Author

Bazeos, Alexandra, primary, Gower, Craig, additional, Swann, Francine, additional, Trask, Peter C, additional, Dixon, Mark, additional, Crompton, Noelle, additional, Kinnersley, Nelson, additional, Al-Sawaf, Othman, additional, Goede, Valentin, additional, Fingerle-Rowson, Günter, additional, and Humphrey, Kathryn, additional

Published
2016
Full Text
View/download PDF

23. Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Author

Nteliopoulos, Georgios, primary, Bazeos, Alexandra, additional, Gerrard, Gareth, additional, Claudiani, Simone, additional, Curry, Ed, additional, Alikian, Mary, additional, Foong, Hui En, additional, Foroni, Letizia, additional, and Apperley, Jane F., additional

Published
2016
Full Text
View/download PDF

27. Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Author

de Lavallade, Hugues, primary, Marin, David, additional, Hart, Melanie, additional, Sekine, Takuya, additional, Gabriel, Ian, additional, Alsuliman, Abdullah, additional, Bazeos, Alexandra, additional, Khoder, Ahmad, additional, Stringaris, Kate, additional, Khorashad, Jamshid, additional, Cooper, Nichola, additional, Milojkovic, Dragana, additional, Foroni, Letizia, additional, Szydlo, Richard M, additional, Chaidos, Aristeidis, additional, Ibrahim, Amr R, additional, Bua, Marco, additional, Goldman, John M, additional, Apperley, Jane F, additional, Kelleher, William P, additional, and Rezvani, Katayoun, additional

Published
2011
Full Text
View/download PDF

28. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

Author

Marin, David, primary, Bazeos, Alexandra, additional, Mahon, Francois-Xavier, additional, Eliasson, Lina, additional, Milojkovic, Dragana, additional, Bua, Marco, additional, Apperley, Jane F., additional, Szydlo, Richard, additional, Desai, Ritti, additional, Kozlowski, Kasia, additional, Paliompeis, Christos, additional, Latham, Victoria, additional, Foroni, Letizia, additional, Molimard, Mathieu, additional, Reid, Alistair, additional, Rezvani, Katy, additional, de Lavallade, Hugues, additional, Guallar, Cristina, additional, Goldman, John, additional, and Khorashad, Jamshid S., additional

Published
2010
Full Text
View/download PDF

29. BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Author

Bazeos, Alexandra, primary, Marin, David, additional, Gerrard, Gareth, additional, Szydlo, Richard, additional, Milojkovic, Dragana, additional, Reid, Alistair, additional, de Lavallade, Hugues, additional, Apperley, Jane F., additional, Goldman, John M, additional, Foroni, Letizia, additional, and Khorashad, Jamshid Sorouri, additional

Published
2009
Full Text
View/download PDF

31. Are HelicobacterSpecies and Enterotoxigenic Bacteroides fragilisInvolved in Inflammatory Bowel Disease?

Author

Basset, Christelle, Holton, John, Bazeos, Alexandra, Vaira, Dino, and Bloom, Stuart

Abstract

The aim of this study was to determine if either Helicobacteror enterotoxigenic Bacteroides fragilis(ETBF) was linked to inflammatory bowel disease (IBD), using PCR. We analyzed the luminal washings and colonic biopsies of 35 patients with IBD and 37 control patients. The presence of Helicobacterwas confirmed in the luminal washing of one IBD patient and three control patients and in the biopsies of two IBD patients. Ten of 28 control patients and 8 of 32 IBD patients had a positive luminal washing for the enterotoxin gene. Six of 33 control patients and 4 of 32 IBD patients had positive biopsies. The prevalence of the enterotoxin gene was higher in IBD patients with active disease compared with patients with inactive disease, although it did not achieve statistical significance. In conclusion, Helicobacterwas not associated with IBD in our population of patients, although ETBF may be associated with active disease.

Published
2004
Full Text
View/download PDF

32. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Author

Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, and Goldman JM

Subjects
Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Humans, Janus Kinases antagonists & inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Molecular Targeted Therapy, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders drug therapy, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells metabolism, Prognosis, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Time Factors, Treatment Outcome, Fusion Proteins, bcr-abl genetics, Myeloproliferative Disorders genetics
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results